UK Markets closed
  • NIKKEI 225

    29,839.71
    -660.34 (-2.17%)
     
  • HANG SENG

    24,221.54
    +122.40 (+0.51%)
     
  • CRUDE OIL

    70.51
    +0.22 (+0.31%)
     
  • GOLD FUTURES

    1,775.00
    +11.20 (+0.63%)
     
  • DOW

    33,919.84
    -50.63 (-0.15%)
     
  • BTC-GBP

    32,565.74
    -2,671.21 (-7.58%)
     
  • CMC Crypto 200

    1,016.33
    -47.52 (-4.47%)
     
  • Nasdaq

    14,746.40
    +32.49 (+0.22%)
     
  • ^FTAS

    4,029.01
    +42.11 (+1.06%)
     

Global Asthma Drugs Market Report 2021-2026 Featuring Chiesi Farmaceutici, Pfizer, Novartis, Roche, AstraZeneca Among Others

·4-min read

Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Asthma Drugs Market (2021-2026) by Medication, Administration, Source, Organization, Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Asthma Drugs Market is estimated to be USD 15.6 Bn in 2021 and is expected to reach USD 23.6 Bn by 2026, growing at a CAGR of 8.6%.

Market Dynamics

The growing incidence of asthma & other breathing syndromes is one of the significant elements increasing the market's progress. Increasing awareness among the population about the accessibility of asthma therapeutics and the growth of blend remedies for the medication of respiratory disorders is another expansion factor for the market.

Some of the other aspects that drive the market are medical sciences development, cumulative healthcare expenditures, widespread research, and upgrades in healthcare structure. Though, stringent government supervisory necessity for the approval of asthma drugs, patent termination of the drugs, and the drugs indicating side effects restrict the market growth.

Market Segmentation

  • By medication, the market is classified as quick-relief medications, long-term control medications, and others. Amongst all, the long-term control medications segment is estimated to hold the highest market share during the forecast period.

  • By Administration, the market is classified as tablets and capsules, liquids, inhalers, injections, and sprays and powders. Amongst all, the tablets and capsules segment is estimated to hold the highest market share during the forecast period.

  • By Source, the market is classified as environment and generic. Amongst the two, the generic segment is estimated to hold the highest market share during the forecast period.

  • By Organization, the market is classified as private and public. Amongst the two, the public segment is estimated to hold the highest market share during the forecast period.

  • By Application, the market is classified as pediatric, adult, and adolescent. Amongst all, the adults segment is estimated to hold the highest market share during the forecast period.

Recent Developments

  • OMRON Healthcare launches a wheeze detection device to pre-empt asthma attacks in kids. - 3rd December 2020

  • Teva Pharmaceutical Industries Launches Two Digital Inhalers For Asthma Patients. - 22nd September 2020

Company Profiles

Some of the companies covered in this report are GlaxoSmithKline, Pfizer, Vectura Group, Boehringer Ingelheim, Roche, Novartis AG, Merck & Co Inc, etc.

Key Topics Covered:

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders

2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study

3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook

4 Market Influencers
4.1 Drivers
4.1.1 Growing Prevalence of Asthma
4.1.2 Increasing Acceptance of Asthma Drugs with Approval from FDA
4.1.3 Government Initiatives Fuels the Awareness of Asthma Drugs
4.2 Restraints
4.2.1 Expiry of Patent Drugs
4.2.2 High Penetration of Generic Drugs
4.3 Opportunities
4.3.1 Technological Advancements in the Development of Asthma Drugs
4.3.2 Introduction of Generic Drugs in Developing Regions
4.4 Challenges
4.4.1 Stringent Government Regulations for the Approval of Asthma Drugs
4.5 Trends

5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis

6 Global Asthma Drugs Market, By Medication
6.1 Introduction
6.2 Quick-Relief Medications
6.3 Long-Term Control Medications
6.4 Others

7 Global Asthma Drugs Market, By Administration
7.1 Introduction
7.2 Tablets And Capsules
7.3 Liquids
7.4 Inhalers
7.5 Injections
7.6 Sprays And Powders

8 Global Asthma Drugs Market, By Source
8.1 Introduction
8.2 Environmental
8.3 Generic

9 Global Asthma Drugs Market, By Organization
9.1 Introduction
9.2 Private
9.3 Public

10 Global Asthma Drugs Market, By Application
10.1 Introduction
10.2 Pediatric
10.3 Adults
10.4 Adolescent

11 Global Asthma Drugs Market, By Geography

12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives

13 Company Profiles

  • Aerocrine AB

  • AMIKO Digital Health

  • AstraZeneca

  • BEXIMCO Pharmaceuticals

  • Boehringer Ingelheim

  • Chiesi Farmaceutici S.p.A.

  • Cipla Inc

  • GlaxoSmithKline,

  • H&T Presspart

  • Merck & Co Inc

  • Mundipharma

  • Novartis AG

  • Omron Healthcare

  • PARI Medical Holding

  • Pfizer

  • PNEUMA Respiratory

  • Roche Holding AG

  • Sunovion Pharmaceuticals

  • Teva Pharmaceutical Industries Ltd

  • Vectura Group

For more information about this report visit https://www.researchandmarkets.com/r/p54pfs

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting